So far, a number of gene- or protein-based cancer biomarkers have been applied to the clinical management of cancer patients with BRCA1/BRCA2 (breast/ovarian cancer) (62), HER-2 (breast cancer) (63), PSA (prostate cancer) (64), and S100 (melanoma) (65) as a few representative examples. The gene discussed is BRCA2; the disease is cancer.